Find stocks with consensus strong buy ratings，and price under 3-month‘s average price target

{
 "show_type": "jgyNewLowcode",
 "config": {
 "type": "iwcapp/aimeScreenerTable",
 "version": "0.0.1",
 "url": "//cdn.ainvest.com/frontResources/s/foiegras/aimeScreenerTable/0.0.1/aimeScreenerTable@0.0.1index.js",
 "query_type": "stock"
 },
 "data": {
 "type": "remote-url",
 "url": "https://cdn.ainvest.com/backtest/agent/session/quant/tangmoming/ai_screener/9be77f2c-7b26-4c49-a4a2-98708c4d68d3.json"
 }
}

The table shows every U.S.–listed stock that meets both criteria:
1. Consensus analyst recommendation is “Strong Buy”; and
2. The current share price is below the average 3-month analyst price target.

Snapshot highlights (sample tickers):

• InflaRx (IFRX) – Shares trade at just ~22 % of the three-month average target, reflecting a deep discount should the company’s anti-inflammatory pipeline deliver.

• Boise Cascade (BCC) – Lumber supplier still screens cheap versus Street targets despite robust U.S. housing demand; upside of roughly 33 % implied.

• Jacobs Solutions (J) – Engineering-services firm offers double-digit upside as infrastructure spending accelerates.

• Belden (BDC) and Sealed Air (SEE) – Both industrial names maintain unanimous buy ratings yet sit below targets, suggesting room for a multiple re-rating.

• Small-cap biotech Nuvectis Pharma (NVCT) also surfaces with substantial price-target headroom.

Use the interactive table to sort by upside percentage, sector, or market cap, and export the list for deeper diligence.